VRDN

Viridian Therapeutics, Inc. (VRDN) 10Y Growth Potential Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Growth

Revenue base remains small at $0.66 per share, leaving room for growth if commercialization scales.

No recent news or fresh metric evidence of a material change in top-line trajectory this month.

Profitability

Gross margin remains extremely high at 99.4%, but operating margin is deeply negative at -5.7% and net margin at -5.4%.

Return on equity is -61.3% and return on invested capital is -39.2%, indicating the business is still far from profitable.

Balance Sheet

Liquidity remains very strong with a current ratio of 16.9x and cash per share of $9.10.

Debt remains manageable with debt-to-equity at 0.37x and net debt-to-EBITDA still low at -0.21x.

Cash Flow

Free cash flow remains negative at -$110.9M TTM, with free cash flow yield at -13.3%.

Operating cash flow is also negative, so the company is still consuming cash rather than generating it.

Valuation

The stock still trades at a very rich EV/sales multiple of 36.5x, which leaves little room for execution misses.

Negative earnings and cash flow keep traditional valuation metrics difficult to anchor despite a strong cash position.

Growth Runway

The balance sheet provides runway for continued R&D and commercialization efforts.

However, the current operating losses mean long-term growth potential still depends on successful pipeline execution.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Viridian Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →